Transparency Document
NCCN Guidelines for B-Cell Lymphomas V.1.2025
| Request Number | Guideline Page | Specific change request | Panel Decision | Comment | Institution Vote |
|---|---|---|---|---|---|
| 3824 |
MANT-6: Mantle Cell Lymphoma | Relapsed/Refractory Disease
Pirtobrutinib Submission from Eli Lilly and Company on 03-22-2024 |
Please consider adding the following footnote wherever non-covalent Bruton's tyrosine kinase inhibitors (BTKi) are listed: “Pirtobrutinib may be used upon progression or intolerance to covalent BTKi therapy.” |
Change not made | Regimens on MANT-A |
Yes: 0 No: 26 Abstain:0 Absent:8 |
| 4277 |
MANT-A (1 of 5)
Acalabrutinib + Bendamustine + Rituximab Submission from AstraZeneca on 06-21-2024 |
Add Acalabrutinib + Bendamustine + Rituximab as a Category 2A preferred regimen for less aggressive induction therapy for Mantle Cell Lymphoma. | Change not made, additional data needed |
Yes: 0 No: 26 Abstain:0 Absent:8 |
|
| 2480 |
MANT-A, 5 OF 5
Ibrutinib + Venetoclax Submission from AbbVie Inc., Janssen Biotech, Inc. on 01-24-2024 |
Ibrutinib + Venetoclax: Clinical data from phase 3 SYMPATICO study are being submitted for your reference regarding ibrutinib + venetoclax for the treatment of R/R mantle cell lymphoma (MCL) to aid the Panel in making recommendations for the NCCN B-cell Lymphomas Guidelines | Change not made | Regimen already in Guidelines. |
Yes: 0 No: 26 Abstain:0 Absent:8 |
| 4489 |
Change requested to the following pages: MANT-A 3 of 5, BCEL-A 2 of 2, BCEL-B 1 of 3, BCEL-C 4 of 6, HGBL-1, BURK-A 1 of 3, HIVLYM-A 1 of 2, PTLD-A
Glucarpidase Submission from BTG on 08-07-2024 |
We request that a footnote be added to the Systemic Therapy sections of the B-Cell Lymphomas Guidelines, specifically in sections where high-dose methotrexate is recommended. Our request is to add a footnote with the following statement “During systemic high-dose methotrexate treatment, consider glucarpidase for delayed methotrexate clearance due to renal impairment.” | Change not made |
Yes: 0 No: 26 Abstain:0 Absent:8 |
|
| 4019 |
MANT-A
Zanubrutinib/Obinutuzumab/Venetoclax Submission from BeiGene USA on 05-20-2024 |
Please list zanubrutinib/obinutuzumab/venetoclax x 24 cycles as a category 2A preferred regimen for aggressive induction therapy and less aggressive induction therapy in patients with TP53 mutation. | Change not made, additional data needed |
Yes: 0 No: 26 Abstain:0 Absent:8 |
|
| 4556 - Internal Request | MANT-A 2 of 5 |
Consider the addition of CD3 x CD20 BsAb glofitamab-gxbm as a treatment option for R/R MCL. Phillips T, et al. JCO 2024:42:Abstract 7008. |
Change made | This is a category 2B recommendation |
Yes: 19 No: 7 Abstain:0 Absent:8 |